Discover and read the best of Twitter Threads about #Flozinators
Most recents (4)
📢📢Tweetorial Alert📢📢 1/14
What are the benefits of Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i)?
What are the benefits of Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i)?
All of the above?
#Flozinators we know #flozins are great & are beneficial in CKD & CV disease, but do they really prevent kidney stones?
How do they work? Does it have anything to do with their effects on magnesium or uric acid? Does the presence of DM make a difference?
#Flozinators we know #flozins are great & are beneficial in CKD & CV disease, but do they really prevent kidney stones?
How do they work? Does it have anything to do with their effects on magnesium or uric acid? Does the presence of DM make a difference?
Stone formation risk ↑ in DM:
↑ uric acid excretion💎
Impaired ammoniagenesis
↓ in urinary pH levels
Dehydration with urinary concentration 🥤
@Momen_Abbasi
renalfellow.org/2023/02/19/kid…
↑ uric acid excretion💎
Impaired ammoniagenesis
↓ in urinary pH levels
Dehydration with urinary concentration 🥤
@Momen_Abbasi
renalfellow.org/2023/02/19/kid…
1) Welcome to our new #accredited #tweetorial which is Part 2 of a 2-part "highlights" program on new #SGLT2i & #DKD data presented at @ERAkidney #ERA22. #Physicians #nurses #pharmacists #PAs and #NPs can all earn 0.5h CE/#CME by following this 🧵!
2a) @ERAkidney #ERA22 is a primary international scientific symposium for interaction and exchange among basic scientists and clinicians working in #Nephrology. Our expert author is Dr. Clara GarcĂa Carro (@ClaraGCarro) from San Carlos Clinical Hospital (Madrid, Spain).
2b) Be sure to check out the first half of this #ERA22 recap from my colleague @shbermejo, and get MORE 🆓CE/#CME at ckd-ce.com/dkd12_ERA22a/. Join me in following @ckd_ce for the BEST in #cardiorenal education delivered entirely by #tweetorial!
In patients with #HFpEF, treatment with #empagliflozin improves clinical outcomes regardless of background #MRA therapy
jacc.org/doi/10.1016/j.…
@JACCJournals #JACC @unic_cardiovasc @JavedButler1 @FaiezZANNAD #MiltonPacker @robmentz @BiykemB @HFpEF @ShelleyZieroth
jacc.org/doi/10.1016/j.…
@JACCJournals #JACC @unic_cardiovasc @JavedButler1 @FaiezZANNAD #MiltonPacker @robmentz @BiykemB @HFpEF @ShelleyZieroth
#MRAs were used in 37% of EMPEROR-Preserved study participants. MRA use was higher in those with a more congested clinical picture, with more HF🏥 within the past 12 months, worse HF symptoms, mildly reduced EF, higher NT-proBNP levels, and more use of loop diuretic agents
The effect of empagliflozin to reduce HF 🏥 was more pronounced in MRA nonusers than in MRA users, particularly in the subgroup of patients with LVEFs ≥50% @HFpEF @DrRyanPDaly @AndrewJSauer @AnastasiaSMihai @DrMarthaGulati @ErinMichos @ShelleyZieroth @mvaduganathan
1/🚨 New #MindtheGap Episode🚨
#MedTwitter, Can you use oral diabetes meds in the hospital? If so, which ones?!
🎶Listen on any podcast app!
iTunes: bit.ly/coreimpodcast
Show Notes: bit.ly/3mGXXRG
CME/MOC: bit.ly/3oVhwbI
#MedTwitter, Can you use oral diabetes meds in the hospital? If so, which ones?!
🎶Listen on any podcast app!
iTunes: bit.ly/coreimpodcast
Show Notes: bit.ly/3mGXXRG
CME/MOC: bit.ly/3oVhwbI
2/ What about DPP-4s?
Usually well tolerated because they ONLY release insulin with a glucose load
So we don’t have to be too concerned if the patient will be NPO!
Usually well tolerated because they ONLY release insulin with a glucose load
So we don’t have to be too concerned if the patient will be NPO!
3/ What about GLP-1s? They act similarly to DPP-4s.
When should we avoid GLP-1s?
When should we avoid GLP-1s?
